Upregulation of Long Non-Coding RNA ENST00000429227.1 Is Correlated with Poor Prognosis in Human Hepatocellular Carcinoma

Yuan Zhao*, Cun-Qing Kong*, Jia-Zhou Ye, Tao Bai, Duo Wang, Miao Chen, Hui-Feng Wang, Xiao-Bo Wang, Jun-Jie Liu, Jie Chen, Hong-Lin Luo, Le-Qun Li

Background: Long non-coding RNAs (lncRNAs) have been shown to play an important regulatory role in many tumors. This study was designed to investigate the expression of lncRNA ENST00000429227.1 in hepatocellular carcinoma (HCC) and to determine whether the expression of lncRNA ENST00000429227.1 affects the prognosis of HCC.

Material/Methods: lncRNA ENST00000429227.1 showing differences in expression between M1 and M2 was screened by microarray expression measurements. Quantitative real-time PCR (qRT-PCR) was used to detect the expression of lncRNA ENST00000429227.1 in 161 HCC patients. The chi-square test was used to evaluate the relationship between the expression of ENST00000429227.1 and clinicopathological parameters. A survival curve was drawn and analyzed by Kaplan-Meier method. Cox regression was used for univariate and multivariate analysis to determine whether lncRNA ENST00000429227.1 is an independent factor of the occurrence and prognosis of HCC.

Results: A total of 3703 differentially expressed lncRNAs were obtained, of which 1777 were upregulated and 1926 were downregulated, with multiple change >1.5. The expression of lncRNA ENST00000429227.1 was upregulated in M2 cells. The expression of lncRNA ENST00000429227.1 in HCC tissues was higher than that in adjacent normal tissues (p<0.05), which was correlated with pathological parameters such as surgical margin (p=0.042), AFP (p=0.022) and Barcelona Clinic Liver Cancer (BCLC) stage (p=0.008). Survival analysis showed that high expression of lncRNA ENST00000429227.1 was associated with a decrease in overall survival (OS) rate of HCC patients. Cox regression analysis showed that high expression of ENST00000429227.1 may be an independent risk factor affecting the prognosis of HCC patients.

Conclusions: The results suggest that upregulation of ENST00000429227.1 is associated with poor prognosis of HCC patients, and may be a new biomarker for the diagnosis of HCC.

MeSH Keywords: Carcinoma, Hepatocellular • Prognosis • RNA, Long Noncoding

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/916551
Background

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world, with high morbidity and mortality rates [1] and it is the second leading cause of cancer death [2]. The incidence of HCC in China accounts for almost half of the global incidence of HCC [3]. Statistics show that China accounts for half of the world’s new cases of and deaths due to HCC [4]. Early HCC can be treated by liver transplantation, hepatectomy, radiofrequency ablation (RFA), and other surgical methods [5]. Transcatheter arterial chemoembolization (TACE) is suitable for the treatment of intermediate-stage HCC patients, while palliative treatment is more often used for advanced-stage HCC patients [6]. However, early-stage HCC usually show few detectable signs, and it was likely that the appropriate treatment time has been missed during detection and diagnosis. The prognosis of HCC patients with symptoms is very poor, and the overall 3-year survival rate is low [7]. Although progress has been made in the diagnosis and treatment of HCC, the incidence and mortality rates of HCC continue to increase. Therefore, efforts have been made to diagnose HCC in its early stage to improve early diagnosis, treatment, and overall prognosis [8].

Studies have found a new class of non-coding RNA, which is between 200 bp and 100 kbp in length, called long non-coding RNA (lncRNA). Upregulated or downregulated lncRNA expression is involved in many diseases, including cancers [9]. HCC-related lncRNAs play critical roles in the tumorigenesis and development of HCC [10]. Increasing numbers of lncRNAs have become new markers of HCC, which can be used for early diagnosis and prognosis evaluation and as an effective therapeutic target for future clinical application [10,11]. Chen et al. reported that IncRNA BLACAT1 affects the proliferation, migration, and invasion of small cell lung cancer (SCLC) cells, and high expression of IncRNA BLACAT1 is associated with clinicopathologic parameters and prognosis of SCLC patients [12]. Wu et al. reported that high expression of lncRNA MAP3K1-2 could be used as a new independent prognostic marker for gastric cancer [13]. Li et al. suggested that the expression of lncRNA AK021443 increased and the overall survival time decreased in HCC, and it might be an important factor affecting the prognosis of HCC patients [14].

Uncontrolled macrophage polarization is usually associated with disease. M1 and M2 macrophages are distributed in various cancer tissues of humans [15]. Among them, M2 macrophages can promote the development of tumors [16]. Changes in the number of M1 cells and M2 cells may affect the prognosis of HCC patients [17]. Liu et al. found that knocking-out lncRNA CCAT1 promoted macrophage polarization, increased numbers of M2 cells, and enhanced prostate cancer invasion [18].

In our previous studies, we used microarrays to detect differential expression of IncRNAs in M1 (classically activated macrophages) and M2 (alternatively activated macrophages) [19]. In the present study, we selected IncRNA ENST00000429227.1, which is downregulated in M1, to study its effect on HCC prognosis. The expression of ENST00000429227.1 in 161 HCC patients was detected, and the relationship between ENST00000429227.1 expression and clinicopathological parameters and overall survival rate of HCC patients was analyzed. To the best of our knowledge, this is the first study to investigate the relationship between ENST00000429227.1 expression and prognosis in HCC patients.

Material and Methods

IncRNA microarray

U937 cells differentiate into different phenotypes (M1 and M2), and 3 pairs of M1 and M2 cells were subjected to microarray analysis.

Patients and samples

The study included 161 HCC patients at Guangxi Tumor Hospital affiliated with Guangxi Medical University. The HCC tissues and adjacent normal liver tissues were taken from 161 patients who were undergoing first-time surgery without previous chemotherapy or radiotherapy. We froze 161 patients’ tissues in liquid nitrogen and stored them at −80°C. HCC diagnosis was based on World Health Organization (WHO) criteria. All patients were followed up by telephone or hospitalization until May 2018. The Ethics Committee of Guangxi Tumor Hospital affiliated with Guangxi Medical University approved the study. We obtained informed consent from all 161 patients. Table 1 lists the clinicopathological parameters of the 161 patients.

Total RNA extraction and quantitative real-time PCR

Total RNA was extracted from the 161 patients’ tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). To analyze the expression of ENST00000429227.1, the PtiteScript™ RT reagent kit (Takara Bio, Inc., Dalian, China) was used for reverse transcription of RNA into cDNA, which was then analyzed by quantitative real-time PCR (qRT-PCR) using SYBR Green Master (RoX) (Takara Bio, Co.). The results are expressed as number of transcripts (standardized by β-actin). Primers are listed in Table 2.

Statistical analysis

SPSS (version 22.0) was used to analyze all the data. GraphPad Prism 5 was used to draw graphs. The chi-square test was used to evaluate the relationship between lncRNA...
| Characteristics               | Number of patients | ENST00000429227.1 | p-Value |
|------------------------------|--------------------|-------------------|---------|
|                              | Low expression     | High expression   |         |
| **Sex**                      |                    |                   |         |
| Female                       | 24                 | 7                 | 17      | 0.278 |
| Male                         | 137                | 56                | 82      |       |
| **Age (years)**              |                    |                   |         |
| ≤55                          | 119                | 42                | 77      | 0.093 |
| >55                          | 42                 | 21                | 21      |       |
| **HBV-DNA (cps/ml)**         |                    |                   |         |
| <5.00*10^2                   | 47                 | 21                | 26      | 0.376 |
| ≥5.00*10^2                   | 113                | 42                | 71      |       |
| **Surgical margin (cm)**     |                    |                   |         |
| ≥2                           | 20                 | 12                | 8       | 0.042 |
| <2                           | 138                | 50                | 88      |       |
| **AFP (ng/l)**               |                    |                   |         |
| <400                         | 74                 | 36                | 38      | 0.022 |
| ≥400                         | 87                 | 27                | 60      |       |
| **CA153 (U/ml)**             |                    |                   |         |
| ≤31.3                        | 150                | 57                | 93      | 0.733 |
| >31.3                        | 9                  | 4                 | 5       |       |
| **PA (mg/L)**                |                    |                   |         |
| ≥170                         | 81                 | 34                | 47      | 0.457 |
| <170                         | 80                 | 29                | 51      |       |
| **Tumor number**             |                    |                   |         |
| <3                           | 129                | 52                | 77      | 0.538 |
| ≥3                           | 32                 | 11                | 21      |       |
| **Portal vein tumor thrombus**|                    |                   |         |
| No                           | 137                | 55                | 82      | 0.528 |
| Yes                          | 24                 | 8                 | 16      |       |
| **BCLC stage**               |                    |                   |         |
| O/A                          | 96                 | 45                | 51      | 0.008 |
| B/C                          | 62                 | 16                | 46      |       |
| **Embolus**                  |                    |                   |         |
| No                           | 116                | 50                | 66      | 0.097 |
| Yes                          | 45                 | 13                | 32      |       |
| **Early recurrence**         |                    |                   |         |
| No/18 months recurrence      | 96                 | 41                | 55      | 0.258 |
| Contains recurrence within 18 months | 65             | 22                | 43      |       |
ENST00000429227.1 expression and clinicopathological characteristics of HCC patients. Kaplan-Meier method was used to draw the OS rate curve, and the statistical significance was evaluated by logarithmic rank test. Cox regression model is used for univariate and multivariate analysis. P<0.05 indicated a statistically significant difference.
Figure 2. (A) Number of differentially expressed IncRNAs. (B) Number of different types of IncRNAs. (C) The normalized intensity of ENST00000429227.1 between the M1 and M2 cells as determined by microarray analysis.

Figure 3. Expression of ENST00000429227.1 in 161 pairs of HCC and adjacent normal tissues. (A) HCC patients were ranked according to difference between ENST00000429227.1 expression in cancer and adjacent normal tissues, and were divided into a high ENST00000429227.1 expression group and a low ENST00000429227.1 expression group. Each experiment was performed in triplicate. (B) Relative expression levels of ENST00000429227.1 in HCC tissues and adjacent normal tissues. A total of 161 pairs of HCC and adjacent normal tissues were used to measure the relative expression levels of ENST00000429227.1. Differences were assessed by paired t test. (C) Kaplan-Meier analysis of ENST00000429227.1 expression in HCC patients and mapping survival curves (P<0.05).
### Table 3. Univariate analysis of overall survival in 161 patients with HCC.

| Variable                          | Univariate analysis | P-value |
|----------------------------------|---------------------|---------|
|                                  | HR                  | 95% CI  |
| Sex                              |                     |         |
| Female                           | 1.306               | 0.622–2.744 | 0.481 |
| Male                             |                     |         |
| Age (years)                      | 0.454               | 0.231–0.893 | 0.022 |
| ≤55                              |                     |         |
| >55                              |                     |         |
| HBV-DNA (cps/ml)                 | 1.320               | 0.748–2.329 | 0.337 |
| ≤5.00*10e2                       |                     |         |
| >5.00*10e2                       |                     |         |
| Surgical margin (cm)             | 1.321               | 0.600–2.908 | 0.489 |
| ≤2                               |                     |         |
| <2                               |                     |         |
| AFP (ng/l)                       | 2.357               | 1.374–4.042 | 0.002 |
| <400                             |                     |         |
| ≥400                             |                     |         |
| CA153 (U/ml)                     | 2.311               | 1.051–5.079 | 0.037 |
| ≤31.3                            |                     |         |
| >31.3                            |                     |         |
| PA (mg/l)                        | 1.696               | 1.023–2.810 | 0.040 |
| ≥170                             |                     |         |
| <170                             |                     |         |
| Tumor number                     | 2.026               | 1.171–3.506 | 0.012 |
| ≤3                               |                     |         |
| ≥3                               |                     |         |
| Portal vein tumor thrombus       | 1.840               | 1.015–3.335 | 0.045 |
| No                               |                     |         |
| Yes                              |                     |         |
| BCLC stage                       | 1.929               | 1.166–3.193 | 0.011 |
| 0/A                              |                     |         |
| B/C                              | 1.929               | 1.166–3.193 | 0.011 |
| Embolus                          | 2.194               | 1.328–3.626 | 0.002 |
| No                               |                     |         |
| Yes                              |                     |         |
| Early recurrence                 | 6.408               | 3.691–11.125 | 0.000 |
| No/18 months recurrence          |                     |         |
| Contains recurrence within 18 months |                   |         |
| ENST00000429227.1 expression     | 1.751               | 1.027–2.986 | 0.039 |
Results

**lncRNA microarray analysis**

A total of 26,200 lncRNAs were obtained from the 2 phenotypes (M1 and M2) of U937 cells, of which 3,703 were differentially expressed during differentiation from M2 to M1 (Figure 1). Among them, 1,777 lncRNAs were upregulated and 1,926 were downregulated (p<0.05; multiple change >1.5) (Figure 2A). Six different types of lncRNAs were found in the 3,703 lncRNAs, including bidirectional, exon overlap, intergenic, intron overlap, intron antisense, and natural antisense (Figure 2B). lncRNA ENST00000429227.1 was bidirectional (multiple change >2, p<0.05) and was expressed at low levels in M1 phenotype and at high levels in M2 phenotype (Figure 2C).

**ENST00000429227.1 is upregulated in human HCC**

We examined the expression of ENST00000429227.1 by qRT-PCR in 161 patients. ENST00000429227.1 was more significantly upregulated in HCC than that in adjacent normal tissues (p<0.05; multiple change >1.5) (Figure 2A). Six different types of lncRNAs were found in the 3,703 lncRNAs, including bidirectional, exon overlap, intergenic, intron overlap, intron antisense, and natural antisense (Figure 2B). lncRNA ENST00000429227.1 was bidirectional (multiple change >2, p<0.05) and was expressed at low levels in M1 phenotype and at high levels in M2 phenotype (Figure 2C).

**ENST00000429227.1 is upregulated in human HCC**

We ranked 161 patients according to the difference in relative expression of ENST00000429227.1 in HCC tissues and adjacent normal tissues (Figure 3A). To explore the relationship between ENST00000429227.1 expression and the clinicopathological characteristics of HCC patients, we assigned the patients with a positive difference to the high expression group, and those with a negative difference were assigned to the low expression group. Statistical analysis showed that ENST00000429227.1 expression was related to incidence margin (p=0.042), AFP (p=0.022), BCLC stage (p=0.008), but not related to sex, age, number of tumors, portal vein cancer thrombus, prealbumin, CA153, early recurrence, embolus, or other parameters (all p>0.05) (Table 1).

**Correlation between lncRNA ENST00000429227.1 expression and the prognosis of HCC patients**

Kaplan-Meier analysis and logarithmic rank test were used to assess whether lncRNA ENST00000429227.1 was associated with the prognosis of HCC patients. The results showed that the overall survival rate in the high expression group was lower than that in the low expression group (p=0.036, Figure 3C). Univariate analysis showed that age, number of tumors, portal vein thrombus, BCLC stage, prealbumin, CA153, early recurrence, embolus, and ENST00000429227.1 expression were significantly correlated with the survival rate (p<0.05, Table 3). Multivariate Cox regression analysis showed that portal vein cancer thrombus, CA153, early recurrence, embolus, and ENST00000429227.1 expression were independent predictive factors of the overall survival rate of HCC patients (p<0.05, Table 4).

**Discussion**

HCC is one of the commonest cancers in the world, with a steadily increasing mortality rate [20], and a new method with high sensitivity and specificity is needed for early diagnosis and early detection of metastasis. Abnormal expression
of IncRNAs can cause many human diseases and cancers [21]. Abnormal expression of IncRNAs in various cancers indicate that IncRNAs may act as a potential tumor suppressor or oncogene [22,23], suggesting that cancer-related IncRNAs can be used as biomarkers for the diagnosis or prediction of cancers, which provides a new therapeutic strategy [22,24]. Quaglia et al. reported that the high expression of IncRNA HOTTIP was associated with shorter overall survival time in HCC patients and can used as a biomarker for predicting HCC [25]. Tu et al. reported that the low expression of GASS was related with poor prognosis of HCC patients [26]. Yang et al. reported that HOTAIR is an independent factor prediction of HCC recurrence in patients receiving liver transplantation, and that no recurrence or shortened survival time were observed in HCC patients with high HOTAIR expression [27].

To sum up, IncRNA ENST00000429227.1 was differentially expressed in 3 pairs of M1 and M2 macrophages (P=0.002), while IncRNA ENST00000429227.1 was differentially expressed in 161 HCC tissues and adjacent normal tissues and it was upregulated in HCC tissues. The high expression of IncRNA ENST00000429227.1 is related to the incision margin, AFP and BCLC stage. Kaplan-Meier analysis showed poor survival of HCC patients with IncRNA ENST00000429227.1 upregulation, and multivariate Cox analysis showed that high expression of IncRNA ENST00000429227.1 was an independent predictor of HCC prognosis.

Conclusions

All these results indicate that IncRNA ENST00000429227.1 is involved in the occurrence and prognosis of HCC. In the future, IncRNA ENST00000429227.1 may be used as a new biomarker of hepatocellular carcinoma and a potential target for HCC treatment. However, the mechanism by which upregulation of IncRNA ENST00000429227.1 occurs in HCC needs further study.

Conflict of interest

None.

References:

1. Akere A, Otegbayo JA: Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma. Singapore Med J, 2007; 48(1): 41–44
2. Bray F, Ferlay J, Soerjomataram I et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin, 2018; 68(6): 394–424
3. Wang H, Song C, Qi Q et al: Functional polymorphisms in IRAKs are related to hepatocellular carcinoma risk in Chinese population. Biomed Res Int, 2018; 2018: 1252849
4. Liao X, Yang C, Huang R et al: Identification of potential prognostic long non-coding RNA biomarkers for predicting survival in patients with hepatocellular carcinoma. Cell Physiol Biochem, 2018; 48(5): 1854–69
5. N’Kontchou G, Aout M, Laurent A et al: Survival after radiofrequency ablation and salvage transplantation in patients with hepatocellular carcinoma and Child-Pugh A cirrhosis. J Hepatol, 2012; 56(1): 160–66
6. Liu J, Ding D, Jiang Z et al: Long non-coding RNA CCAT1/miR-148a/PKCIzeta prevents cell migration of prostate cancer by altering macrophage polarization. Prostate, 2019; 79(1): 105–112
7. Luo HL, Chen J, Luo T et al: Downregulation of macrophage-derived T-UCR uc.306 associates with poor prognosis in hepatocellular carcinoma. Cell Physiol Biochem, 2017; 42(4): 1526–39
8. Quagliata L, Matter MS, Piscuoglio S et al: Long non-coding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology (Baltimore, MD), 2011; 54(5): 1679–89
9. Shi X, Sun M, Liu H et al: Long non-coding RNAs: A new player in cancer. Eur Rev Med Pharmacol Sci, 2018; 22(4): 1526–39
10. Li YC, Wang D, Zhu GY: Increased expression of long noncoding RNA AK021443 predicts worse clinical outcome in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 2018; 22(15): 4855–60
11. Ye Y, Xu Y, Lai Y et al: Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization. J Cell Biochem, 2018; 119(3): 2951–63
12. Yuan A, Hisao Y, Chen HY et al: Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci Rep, 2015; 5: 14273
13. Yoshin S, Singh AR, Zuili M et al: Rac2 controls tumor growth, metastasis and M1–M2 macrophage differentiation in vivo. PLoS One, 2014; 9(4): e95893
14. Li YC, Wang D, Zhu GY: Increased expression of long noncoding RNA AK021443 predicts worse clinical outcome in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 2018; 22(15): 4855–60
15. Ye Y, Xu Y, Lai Y et al: Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization. J Cell Biochem, 2018; 119(3): 2951–63
16. Yuan A, Hisao Y, Chen HY et al: Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci Rep, 2015; 5: 14273
17. Yoshin S, Singh AR, Zuili M et al: Rac2 controls tumor growth, metastasis and M1–M2 macrophage differentiation in vivo. PLoS One, 2014; 9(4): e95893
18. Liu J, Ding D, Jiang Z et al: Long non-coding RNA CCAT1/miR-148a/PKCIzeta prevents cell migration of prostate cancer by altering macrophage polarization. Prostate, 2019; 79(1): 105–112
19. Luo HL, Chen J, Luo T et al: Downregulation of macrophage-derived T-UCR uc.306 associates with poor prognosis in hepatocellular carcinoma. Cell Physiol Biochem, 2017; 42(4): 1526–39
20. Yang F, Zhang L, Luo S et al: Long non-coding RNA HOTAIR expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology (Baltimore, MD), 2011; 54(5): 1679–89
21. Sanchez Y, Mahtre M: Long non-coding RNAs: challenges for diagnosis and therapies. Nucleic Acid Ther, 2013; 23(1): 15–20
22. Shi X, Sun M, Liu H et al: Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Lett, 2013; 339(2): 159–66
23. Zhang H, Chen Z, Wang X et al: Long non-coding RNA: A new player in cancer. J Hematol Oncol, 2013; 6: 37
24. Yang F, Zhang L, Luo S et al: Long non-coding RNA HOTAIR expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology (Baltimore, MD), 2011; 54(5): 1679–89
25. Sanchez Y, Mahtre M: Long non-coding RNAs: challenges for diagnosis and therapies. Nucleic Acid Ther, 2013; 23(1): 15–20
26. Shi X, Sun M, Liu H et al: Long non-coding RNAs: A new frontier in the study of human diseases. Cancer Lett, 2013; 339(2): 159–66
27. Zhang H, Chen Z, Wang X et al: Long non-coding RNA: A new player in cancer. J Hematol Oncol, 2013; 6: 37
28. Tang J, Jiang R, Deng L et al: Circulation long non-coding RNAs act as biomarkers for predicting tumorogenesis and metastasis in hepatocellular carcinoma. Oncotarget, 2015; 6(6): 4505–15
29. Quaglia L, Matter MS, Piscuoglio S et al: Long non-coding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology (Baltimore, MD), 2014; 59(3): 911–23
30. Tu ZQ, Li RJ, Mei JZ et al: Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol, 2011; 18(5): 1243–50